Welcome to visit Zhongnan Medical Journal Press Series journal website!
Zhongnan Medical Journal Press Series of Journals Center for Evidence-Based and Translational Medicine of Wuhan University

The title
  • The title
  • The keywords
  • The author
Submit中文版

HomeArticlesVol 30,2020 No.1Detail

A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (Full version)

Published on Feb. 01, 2020Total Views: 124815 timesTotal Downloads: 30682 timesDownloadMobile

Author: Ying-Hui JIN 1 Lin CAI 2 Zhen-Shun CHENG 3 Hong CHENG 4 Tong DENG 1, 5 Yi-Pin FAN 6, 7 Cheng FANG 1 Di HUANG 1 Lu-Qi HUANG 6, 7 Qiao HUANG 1 Yong HAN 2 Bo HU 8 Fen HU 8 Bing-Hui LI 1, 5 Yi-Rong LI 9 Ke LIANG 10 Li-Kai LIN 2 Li-Sha LUO 1 Jing MA 8 Lin-Lu MA 1 Zhi-Yong PENG 8 Yun-Bao PAN 9 Zhen-Yu PAN 11 Xue-Qun REN 5 Hui-Min SUN 12 Ying WANG 13 Yun-Yun WANG 1 Hong WENG 1 Chao-Jie WEI 3 Dong-Fang WU 4 Jian XIA 14 Yong XIONG 10 Hai-Bo XU 15 Xiaomei YAO 16 Yu-Feng YUAN 2 Tai-sheng YE 17 Xiao-Chun ZHANG 15 Ying-Wen ZHANG 17 Yin-Gao ZHANG 2 Hua-Min ZHANG 6, 7 Yan ZHAO 14 Ming-Juan ZHAO 1 Hao ZI 1, 5 Xian-Tao ZENG 1, 18* Yong-Yan WANG 6, 7* Xing-Huan WANG 1, 2* for the Zhongnan Hospital of Wuhan University Novel Coronavirus Management and Research Team Evidence-Based Medicine Chapter of China International Exchange and Promotive Association for Medical and Health Care (CPAM) Technology Innovation Alliance

Affiliation: 1. Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, China 2. Institute of Hospital Management, Wuhan University, Wuhan 430071, China 3. Department of Respiratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, China 4. Department of Pharmacy, Zhongnan Hospital of Wuhan University, Wuhan 430071, China 5. Institute of Evidence-Based Medicine and Knowledge Translation, Henan University, Kaifeng 475000, China 6. China Academy of Chinese Medical Sciences, Beijing 100700, China 7. China Center for Evidence Based Traditional Chinese Medicine (CCEBTCM), Beijing 100700, China 8. Department of Critical Care Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, China 9. Department of Clinical Laboratory, Zhongnan Hospital of Wuhan University, Wuhan 430071, China 10. Department of Infectious Diseases, Zhongnan Hospital of Wuhan University, Wuhan 430071, China 11. Division of Medical Affairs, Zhongnan Hospital of Wuhan University, Wuhan 430071, China 12. Division of Nursing Affairs, Zhongnan Hospital of Wuhan University, Wuhan 430071, China 13. Office of Nosocomial Infection Control, Zhongnan Hospital of Wuhan University, Wuhan 430071, China 14. Emergency Center, Zhongnan Hospital of Wuhan University, Wuhan 430071, China 15. Department of Radiology, Zhongnan Hospital of Wuhan University, Wuhan 430071, China 16. Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario L8S 4L8, Canada 17. Department of Traditional Chinese Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, China 18. Global Health Institute, Wuhan University, Wuhan 430072, China

Keywords: 2019-nCoV COVID-19 Respiratory disease Pneumonia Infectious diseases Rapid advice guideline Clinical practice guideline Evidence-based medicine

DOI: 10.12173/j.issn.1004-5511.2020.01.09

Reference: Jin YH, Cai L, Cheng ZS, Cheng H, Deng T, Fan YP, Fang C, Huang D, Huang LQ, Huang Q, Han Y, Hu B, Hu F, Li BH, Li YR, Liang K, Lin LK, Luo LS, Ma J,Ma LL, Peng ZY, Pan YB, Pan ZY, Ren XQ, Sun HM, Wang Y, Wang YY, Weng H, Wei CJ, Wu DF, Xia J, Xiong Y, Xu HB, Yao XM, Yuan YF, Ye TS, Zhang XC, Zhang YW, Zhang YG, Zhang HM, Zhao Y, Zhao MJ, Zi H, Zeng XT, Wang YY, Wang XH, Zhongnan Hospital of Wuhan University Novel Coronavirus Management and Research Team, Evidence-Based Medicine Chapter of China International Exchange and Promotive Association for Medical and Health Care (CPAM). A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (Full version)[J].Yixue Xinzhi Zazhi, 2020, 30(1): 35-65. DOI: 10.12173/j.issn.1004-5511.2020.01.09.[Article in Chinese]

  • Abstract
  • Full-text
  • References
Abstract

Without the.

Full-text
Please download the PDF version to read the full text: download
References

1.World Health Organization. WHO handbook for guideline development, 2nd ed [EB/OL]. (2014) [2020-01-22]. https://apps.who.int/iris/handle/10665/145714.

2.Norris SL. WHO and Rapid Advice Guidelines: History and Future Directions [EB/OL]. [2020-01-22]. https://g-i-n.net/conference/past-conferences/10th-conference/monday/10-00-am-to-1-00-pm/norris-62.pdf/view.

3.Holger J, Schünemann, Zhang Y, et al. Distinguishing opinion from evidence in guidelines[J]. BMJ, 2019, 366: l4606. DOI: 10.1136/bmj.l4606.

4.Schünemann H, Brożek J, Guyatt G, et al. GRADE Handbook, GRADE working group [EB/OL]. [2020-01-22]. https://gdt.gradepro.org/app/handbook/handbook.html. 

5.Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations [J]. BMJ, 2008, 336(7650): 924-926. DOI: 10.1136/bmj.39489.470347.AD.

6.Alonso-Coello P, Schünemann HJ, Moberg J, et al. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction [J]. BMJ, 2016, 353: i2016. DOI: 10.1136/bmj.i2016.

7.Legault K, Schunemann H, Hillis C, et al. McMaster RARE-Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome [J]. J Thromb Haemost,2018, 16(8): 1656–64. DOI: 10.1111/jth.14192.

8.靳英辉, 蔡林, 程真顺, 等. 新型冠状病毒（2019-nCoV）感染的肺炎诊疗快速建议指南（标准版）[J]. 解放军医学杂志, 2020, 45(1):1-20. DOI: 10.11855/j.issn.0577-7402.2020.01.01. [Jin YH, Cai L, Cheng ZS, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (Standard version) [J]. Medical Journal of Chinese People’s Liberation Army, 2020, 45(1):1-20.]

9.Chan JFW, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet, 2020, pii: S0140-6736(20)30154-9. DOI: 10.1016/S0140-6736(20)30154-9.

10.国家卫生健康委员会卫生应急办公室. 截至1月26日24时新型冠状病毒感染的肺炎疫情最新情况 [EB/OL]. (2020-01-26) [2020-01-26]. http://www.nhc.gov.cn/xcs/yqtb/202001/3882fdcdbfdc4b4fa4e3a829b62d518e.shtml.

11.Zhou P, Yang X, Wang X, et al. Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin[J]. bioRxiv,2020:2020-2021. (Preprint version, January 23, 2020.) DOI: 10.1101/2020.01.22.914952.

12.Perlman S. Another Decade, Another Coronavirus[J]. N Engl J Med, 2020. [published online ahead of print January 24, 2020]. DOI: 10.1056/NEJMe2001126.

13.国家卫生健康委员会办公厅. 国家中医药管理局办公室.关于印发新型冠状病毒感染的肺炎诊疗方案（试行第四版）的通知 [EB/OL]. (2020-01-28) [2020-01-28]. http://bgs.satcm.gov.cn/zhengcewenjian/2020-01-28/12576.html.

14.Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019 [J]. N Engl J Med, 2020, DOI: 10.1056/NEJMoa2001017.

15.国家卫生健康委办公厅, 国家中医药管理局办公室. 关于印发新型冠状病毒感染的肺炎诊疗方案（试行第三版）的通知[EB/OL]. (2020-01-23) [2020-01-23]. http://www.nhc.gov.cn/xcs/zhengcwj/202001/f492c9153ea9437bb587ce2ffcbee1fa.shtml.

16.国务院新闻办公室.新闻办就新型冠状病毒感染的肺炎疫情联防联控工作有关情况举行发布会[EB/OL]. (2020-01-26) [2020-01-26]. http://www.scio.gov.cn/xwfbh/xwbfbh/wqfbh/42311/42478/index.htm.

17.17Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China [J]. Lancet, 2020, pii: S0140-6736(20)30183-5. DOI: 10.1016/S0140-6736(20)30183-5.

18.World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected [EB/OL].(2020-1-12) [2020-1-26]. https://www.who.int/internal-publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected.

19.Centers for Disease Control and Prevention. CDC: Healthcare Professionals-Interim Guidance for Healthcare Professionals[EB/OL]. [2020-1-26]. https://www.cdc.gov/coronavirus/2019-nCoV/clinical-criteria.html.

20.中华人民共和国国家卫生健康委员会.传染性非典型肺炎（SARS）诊疗方案（2004版）[EB/OL]. (2005-05-24) [2020-1-26]. http://www.nhc.gov.cn/uploadfile/200505/2005524143254605.doc.

21.中华人民共和国国家卫生健康委员会.中东呼吸综合征病例诊疗方案（2015年版）[EB/OL]. (2015-06-12) [2020-1-26]. http://www.nhc.gov.cn/ewebeditor/uploadfile/2015/06/20150612155708721.docx.

22.李莉, 任美吉, 张岩岩, 等. 1例确诊新型冠状病毒（2019-nCoV）肺炎患者的肺部CT表现（附SARS病理及鉴别诊断）[J]. 医学新知, 2020, 30(1): 4-6. DOI: 10.12173/j.issn.1004-5511.2020.01.03. [Li L, Ren MJ, Zhang YY, et al. Lung CT image of a confirmed case of the 2019 novel coronavirus (2019-nCoV) infected pneumonia (With differential diagnosis of the SARS)[J]. New Medicine, 2020, 30(1): 4-6.]

23.World Health Organization. Guidelines for the global surveillance of severe acute respiratory syndrome (SARS)[EB/OL].(2004-10) [2020-1-26]. http://www.who.int/csr/resources/publications/WHO_CDS_CSR_ARO_2004_1/en/index.html.

24.Centers for Disease Control and Prevention. Severe Acute Respiratory Syndrome (SARS) Investigation Guideline[EB/OL].(2018-05-11) [2020-1-26]. http://www.cdc.gov/sars/guidance/index.html.

25.国家卫生健康委员会疾病预防控制局.新型冠状病毒感染的肺炎防控方案（第二版） [EB/OL]. (2020-01-22) [2020-1-26]. http://www.nhc.gov.cn/xcs/zhengcwj/202001/c67cfe29ecf1470e8c7fc47d3b751e88.shtml.

26.World Health Organization. Home care for patients with suspected novel coronavirus (nCoV) infection presenting with mild symptoms and management of contacts[EB/OL]. (2020-01-20) [2020-01-26]. https://www.who.int/publications-detail/home-care-for-patients-with-suspected-novel-coronavirus-(ncov)-infection-presenting-with-mild-symptoms-and-management-of-contacts.

27.Kim JY, Song JY, Yoon YK, et al. Middle East Respiratory Syndrome Infection Control and Prevention Guideline for Healthcare Facilities [J]. Infect Chemother, 2015, 47(4): 278-302.DOI: 10.3947/ic.2015.47.4.278.

28.王莹, 林丽开.新型冠状病毒(2019-nCoV)疑似感染患者及其密切接触者居家隔离中南医院建议指南[EB/OL]. (2020-01-24) [2020-01-26]. https://mp.weixin.qq.com/s/xFO10WAFB9OUnM7VN92R2w.

29.国家卫生健康委员会疾病预防控制局.关于印发新型冠状病毒感染不同风险人群防护指南和预防新型冠状病毒感染的肺炎口罩使用指南的通知[EB/OL]. (2020-01-31) [2020-01-31]. http://www.nhc.gov.cn/jkj/s7916/202001/a3a261dabfcf4c3fa365d4eb07ddab34.shtml

30.World Health Organization. Infection prevention and control during health care when novel coronavirus (nCoV) infection is suspected[EB/OL]. (2020-01-25) [2020-01-26] https://www.who.int/publications-detail/infection-prevention-and-control-during-health-care-when-novel-coronavirus-(ncov)-infection-is-suspected-20200125. 

31.World Health Organization. WHO advice for international travel and trade in relation to the outbreak of pneumonia caused by a new coronavirus in China (10 January 2020) [EB/OL]. (2020-01-10) [2020-01-26]. https://www.who.int/ith/2020-0901_outbreak_of_Pneumonia_caused_by_a_new_coronavirus_in_C/en/.

32.Centers for Disease Control and Prevention. CDC: travelers' health - novel coronavirus in China[EB/OL]. (2020-01-06) [2020-01-26]. https://wwwnc.cdc.gov/travel/notices/watch/novel-coronavirus-china. 

33.Centers for Disease Control and Prevention. CDC: 2019 Novel Coronavirus Home-About 2019-nCoV-Prevention and Treatment[EB/OL]. (2020-01-29) [2020-01-29]. https://www.cdc.gov/coronavirus/2019-ncov/about/prevention-treatment.html.

34.Centers for Disease Control and Prevention. CDC:2019 Novel Coronavirus Home-Healthcare Professionals-Interim Infection Prevention and Control Recommendations for Patients with Known or Patients Under Investigation for 2019 Novel Coronavirus (2019-nCoV) in a Healthcare Setting[EB/OL]. (2020-01-28) [2020-01-29]. https://www.cdc.gov/coronavirus/2019-nCoV/hcp/infection-control.html.

35.Centers for Disease Control and Prevention. CDC: 2019 Novel Coronavirus Home-Healthcare Professionals-Interim Guidance for Implementing Home Care of People Not Requiring Hospitalization for 2019 Novel Coronavirus (2019-nCoV) [EB/OL]. (2020-01-31) [2020-01-31]. https://www.cdc.gov/coronavirus/2019-ncov/hcp/guidance-home-care.html.

36.Centers for Disease Control and Prevention. CDC: Travelers’ Health-Destinations-China Traveler View[EB/OL]. (2020-01-13) [2020-01-26]. https://wwwnc.cdc.gov/travel/destinations/traveler/none/china#travel-notices

37.Centers for Disease Control and Prevention. CDC: Infection Control - Isolation Precautions [EB/OL]. (2019-07-22) [2020-01-26]. https://www.cdc.gov/infectioncontrol/guidelines/isolation/index.html.

38.Dawson P, Malik MR, Parvez F, et al. What Have We Learned About Middle East Respiratory Syndrome Coronavirus Emergence in Humans? A Systematic Literature Review[J]. Vector Borne Zoonotic Dis, 2019, 19(3): 174-192. DOI:10.1089/vbz.2017.2191.

39.Han HJ, Liu JW,Yu H, et al. Neutralizing Monoclonal Antibodies as Promising Therapeutics against Middle East Respiratory Syndrome Coronavirus Infection[J]. Viruses, 2018,10(12):680. DOI:10.3390/v10120680.

40.中国疾病预防控制中心. 国家病原微生物资源库再次公布首株环境样本分离的新型冠状病毒信息[EB/OL]. (2020-01-27) [2020-01-29]. http://www.chinacdc.cn/jkzt/crb/zl/szkb_11803/jszl_11811/202001/t20200127_211475.html.

41.王卫国, 胡姮, 宋璐, 等. 不典型新型冠状病毒（2019-nCoV）感染的肺炎的影像学表现及诊断: 14例分析[J]. 医学新知, 2020, 30(1): 7-9. DOI: 10.12173/j.issn.1004-5511.2020.01.04. [Wang W, Hu H, Song L, et al. Image of pulmonary and diagnosis of atypicalnovel coronavirus (2019-nCoV) infected pneumonia: case series of 14 patients [J]. New Medicine, 2020, 30(1): 7-9.]

42.Centers for Disease Control and Prevention. Novel Coronavirus (2019-nCoV) and You[EB/OL]. [2020-01-30]. [2020-01-30]. https://www.cdc.gov/coronavirus/2019-ncov/about/index.html.

43.Kenneth M. Severe acute respiratory syndrome (SARS). UpToDate, 2019. [2020-01-26]. https://www.uptodate.com/contents/severe-acute-respiratory-syndrome-sars.

44.Peiris JS, Yuen KY, Osterhaus AD, et al. The severe acute respiratory syndrome[J]. N Engl J Med, 2003, 349(25):2431-2441. DOI:10.1056/NEJMra032498.

45.World Health Organization. Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human case[EB/OL]. (2020-01-14). [2020-01-26]. https://www.who.int/health-topics/coronavirus/laboratory-diagnostics-for-novel-coronavirus.

46.江华, 邓洪飞, 王宇, 等. 洛匹那韦/利托那韦（LPV/r）用于2019新型冠状病毒肺炎的治疗可能性：基于既往冠状病毒肺炎研究的快速系统评价[J]. 中华急诊医学杂志, 2020, 29(2):182-186. DOI: 10.3760/cma.j.issn.1671-0282.2020.02.011. [Jiang H, Deng HF, Wang Y, et al. Possibility of lopinavir / ritonavir (LPV / r) for the treatment of new coronavirus pneumonia in 2019: a rapid systematic review based on previous studies of coronavirus pneumonia [J]. Journal of Emergency Medicine, 2020, 29 (2): 182-186.]

47.Chu CM, Cheng VC, Hung IF, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings[J]. Thorax, 2004, 59(3): 252-256. DOI: 10.1136/thorax.2003.012658.

48.Lai, ST. Treatment of severe acute respiratory syndrome[J]. Eur J Clin Microbiol Infect Dis, 2005, 24(9): 583-591. DOI: 10.1007/s10096-005-0004-z.

49.Chan KS, Lai ST, Chu CM, et al. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study[J]. Hong Kong Med J, 2003, 9(6): 399-406.

50.Brigitte M, Arti B, Stephan A, et al. MERS-COV disease associated ARDS -A case report[J]. Crit Care Med, 2015, 43(12): 308. DOI: 10.1097/01.ccm.0000475056.21112.47.

51.Omrani AS, Saad MM, Baig K, et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study[J]. Lancet Infect Dis, 2014, 14(11): 1090-1095. DOI: 10.1016/S1473-3099(14)70920-X.

52.Arabi YM, Shalhoub S, Mandourah Y, et al. Ribavirin and Interferon Therapy for Critically Ill Patients With Middle East Respiratory Syndrome: A Multicenter Observational Study[J]. Clin Infect Dis, 2019, pii: ciz544. DOI: 10.1093/cid/ciz544.

53.Falzarano D, de Wit E, Rasmussen AL, et al. Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques[J]. Nat Med, 2013, 19(10): 1313-1317. DOI: 10.1038/nm.3362.

54.Chan JF, Yao Y, Yeung ML et al. Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset[J]. J Infect Dis, 2015, 212(12): 1904-1913. DOI: 10.1093/infdis/jiv392.

55.Bernard GR, Luce JM, Sprung CL, et al. High-dose corticosteroids in patients with the adult respiratory distress syndrome[J]. N Engl J Med, 1987, 317(25): 1565-1570. DOI: 10.1056/NEJM198712173172504.

56.Weigelt J A, Norcross JF, Borman KR, et al. Early steroid therapy for respiratory failure[J]. Arch Surg, 1985, 120(5): 536-540. DOI: 10.1001/archsurg.1985.01390290018003.

57.Meduri GU, Headley AS, Golden E, et al. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial[J]. JAMA, 1998, 280(2): 159-165. DOI: 10.1001/jama.280.2.159.

58.赵子文, 张复春, 许敏, 等. 广州地区2003年春季传染性非典型肺炎190例临床分析[J]. 中华医学杂志, 2003, 83(9): 713-718. DOI: 10.3760/j:issn:0376-2491.2003.09.003. [Zhao ZW, Zhang FC, Xu M, et al. Clinical analysis of 190 cases of outbreak with atypical pneumonia in Guangzhou in spring[J]. Zhonghua Yi Xue Za Zhi, 2003, 83(9): 713-718.]

59.萧建中, 马丽, 高捷, 等. 超大剂量糖皮质激素治疗重症急性呼吸综合征致糖尿病的风险和对策[J]. 中华内科杂志, 2004, 43(3): 179-182. DOI: 10.3760/j.issn:0578-1426.2004.03.007. [Xiao JZ, Ma L, Gao J, et al. Glucocorticoid-induced diabetes in severe acute respiratory syndrome: the impact of high dosage and duration of methylprednisolone therapy[J]. Zhonghua Nei Ke Za Zhi, 2004, 43(3): 179-182.]

60.Guo KJ, Zhao FC, Guo Y, et al. The influence of age, gender and treatment with steroids on the incidence of osteonecrosis of the femoral head during the management of severe acute respiratory syndrome: a retrospective study[J]. Bone Joint J, 2014, 96-B(2):259-262. DOI: 10.1302/0301-620X.96B2.31935.

61.刘朝晖, 李子荣, 张念非, 等. SARS后双侧股骨头坏死进展前瞻性分析[J].中国骨与关节损伤杂志, 2010, 25(10): 889-893. [Liu Zhaohui, Li Zirong, Zhang Nianfei, et al. Prospective analysis of the progress of bilateral femoral head necrosis after SARS [J] .Chinese Journal of Bone and Joint Injury, 2010, 25 (10): 889-893.]

62.唐烽明, 王景贵, 赵栋, 等. 激素药源性股骨头坏死及骨质疏松49例中期分析[J]. 中国骨与关节损伤杂志, 2012, 27(2):106-108. [Tang Yiming, Wang Jinggui, Zhao Dong, et al. Mid-term analysis of glucocorticoid induced femoral head necrosis and osteoporosis in 49 patients[J]. Chinese Journal of Bone and Joint Injury, 2012, 27 (2): 106-108.]

63.陆伟, 张洪生, 王凤梅, 等. 重症SARS患者32例治疗初探[J]. 中国危重病急救医学, 2003, 15(8): 492-494. DOI: 10.3760/j.issn:1003-0603.2003.08.015. [Lu W, Zhang H, Wang F. et al. Preliminary analysis of treatment in 32 patients with critical severe acute respiratory syndrome[J]. Chinese critical care medicine, 2003, 15(8):492-494.]

64.Zhao J, Perera RA, Kayali G, et al. Passive immunotherapy with dromedary immune serum in an experimental animal model for Middle East Respiratory Syndrome coronavirus infection[J]. J Virol, 2015, 89(11): 6117-6120. DOI: 10.1128/JVI.00446-15.

65.Cheng Y, Wong R, Soo YO, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong[J]. Eur J Clin Microbiol Infect Dis, 2005, 24(1): 44-46. DOI: 10.1007/s10096-004-1271-9.

66.Yeh KM, Chiueh TS, Siu LK, et al. Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital[J]. J Antimicrob Chemother, 2005, 56(5): 919-922. DOI: 10.1093/jac/dki346.

67.伍卫, 王景峰, 刘品明, 等. 医院聚集性感染的重症急性呼吸综合征96例临床分析[J]. 中华内科杂志, 2003, 42(7): 453-457. DOI: 10.3760/j.issn:0578-1426.2003.07.003. [Wu W, Wang JF, Liu PM, et al. . Clinical features of 96 patients with severe acute respiratory syndrome from a hospital outbreak[J]. Zhonghua Nei Ke Za Zhi, 2003, 42(7): 453-457.]

68.李仲智, 申昆玲, 魏新苗, 等. 18例儿童严重急性呼吸综合征临床分析[J]. 中华儿科杂志, 2003,41(8): 574-577. DOI: 10.3760/j.issn:0578-1310.2003.08.005. [Li ZZ, Shen KL, Wei XM, et al. Clinical analysis of pediatric SARS cases in Beijing[J]. Zhonghua Er Ke Za Zhi, 2003, 41(8): 574-577.]

69.Soo YO, Cheng Y, Wong R, et al. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients[J]. Clin Microbiol Infect, 2004, 10(7): 676-678. DOI: 10.1111/j.1469-0691.2004.00956.x.

70.Mair-Jenkins J, Saavedra-Campos M, Baillie JK, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis[J]. J Infect Dis, 2015, 211(1): 80-90. DOI: 10.1093/infdis/jiu396.

71.Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses[J]. Sci Transl Med, 2017, 9(396). pii: eaal3653. DOI: 10.1126/scitranslmed.aal3653.

72.Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV[J]. Nat Commun, 2020, 11(1): 222. DOI: 10.1038/s41467-019-13940-6.

73.Holshue ML, DeBolt C, Lindquist S, et al. First Case of 2019 Novel Coronavirus in the United States[J]. N Engl J Med.[published online ahead of print January 31, 2020]. DOI: 10.1056/NEJMoa2001191.

74.ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, et al. Acute respiratory distress syndrome: the Berlin Definition[J]. JAMA, 2012, 307(23):2526-33. DOI: 10.1001/jama.2012.5669.

75.Griffiths MJD, McAuley DF, Perkins GD, et al. Guidelines on the management of acute respiratory distress syndrome[J]. BMJ Open Respir Res, 2019, 6(1): e000420. DOI: 10.1136/bmjresp-2019-000420.

76.Fan E, Del Sorbo L, Goligher EC, et al. An Official American Thoracic Society/European Society of Intensive Care Medicine/Society of Critical Care Medicine clinical practice guideline: mechanical ventilation in adult patients with acute respiratory distress syndrome[J]. Am J Respir Crit Care Med, 2017, 195(9):1253-1263. DOI: 10.1164/rccm.201703-0548ST.

77.Kasenda B, Sauerbrei W, Royston P, et al. Multivariable fractional polynomial interaction to investigate continuous effect modifiers in a meta-analysis on higher versus lower PEEP for patients with ARDS[J]. BMJ Open，2016, 6(9): e011148. DOI: 10.1136/bmjopen-2016-011148.

78.Munshi L, Del Sorbo L, Adhikari NKJ, et al. Prone position for acute respiratory distress syndrome. A systematic review and meta-analysis[J]. Ann Am Thorac Soc, 2017, 14(suppl 4): S280-S288. DOI: 10.1513/AnnalsATS.201704-343OT.

79.Beitler JR, Shaefi S, Montesi SB, et al. Prone positioning reduces mortality from acute respiratory distress syndrome in the low tidal volume era: a meta-analysis[J]. Intensive Care Med, 2014, 40(3): 332-341. DOI: 10.1007/s00134-013-3194-3.

80.Bloomfield R, Noble DW, Sudlow A. Prone position for acute respiratory failure in adults[J]. Cochrane Database Syst Rev, 2015, (11): CD008095. DOI: 10.1002/14651858.CD008095.pub2.

81.严重急性低氧性呼吸衰竭急诊治疗专家共识组. 严重急性低氧性呼吸衰竭急诊治疗专家共识[J]. 中华急诊医学杂志, 2018, 27(8): 844-849. DOI:10.3760/cma.j.issn.1671-0282.2018.08.005. [Expert Consensus Group for Emergency Treatment of Severe Acute Hypoxic Respiratory Failure (2018). Expert Consensus for Emergency Treatment of Severe Acute Hypoxic Respiratory Failure [J]. Chinese Journal of Emergency Medicine, 2018, 27 (8): 844-849.]

82.Papazian L, Forel JM, Gacouin A, et al. Neuromuscular blockers in early acute respiratory distress syndrome[J]. N Engl J Med, 2010, 363(12): 1107-1116. DOI: 10.1056/NEJMoa1005372.

83.Goligher EC, Munshi L, Adhikari NKJ, et al. High-frequency oscillation for adult patients with acute respiratory distress syndrome. A systematic review and meta-analysis[J]. Ann Am Thorac Soc, 2017, 14(suppl 4): S289-S296. DOI: 10.1513/AnnalsATS.201704-341OT.

84.Sud S, Sud M, Friedrich JO, et al. High-frequency oscillatory ventilation versus conventional ventilation for acute respiratory distress syndrome[J]. Cochrane Database Syst Rev, 2016, (4): CD004085. DOI: 10.1002/14651858.CD004085.pub4.

85.Meade MO, Young D, Hanna S, et al. Severity of hypoxemia and effect of high-frequency oscillatory ventilation in acute respiratory distress syndrome[J]. Am J Respir Crit Care Med, 2017, 196(6): 727-733. DOI: 10.1164/rccm.201609-1938OC.

86.Munshi L, Walkey A, Goligher E, et al. Venovenous extracorporeal membrane oxygenation for acute respiratory distress syndrome: a systematic review and meta-analysis[J]. Lancet Respir Med, 2019, 7(2): 163-172. DOI: 10.1016/S2213-2600(18)30452-1.

87.Combes A, Hajage D, Capellier G, et al. Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome[J]. N Engl J Med, 2018, 378(21): 1965-1975. DOI: 10.1056/NEJMoa1800385.

88.Rice TW, Wheeler AP, Thompson BT, et al. Enteral omega-3 fatty acid, gamma-linolenic acid, and antioxidant supplementation in acute lung injury[J]. JAMA, 2011, 306(14): 1574-1581. DOI: 10.1001/jama.2011.1435.

89.National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network, Matthay MA, Brower RG, et al. Randomized, placebo-controlled clinical trial of an aerosolized β2-agonist for treatment of acute lung injury[J]. Am J Respir Crit Care Med, 2011, 184(5): 561-568. DOI: 10.1164/rccm.201012-2090OC.

90.Gao Smith F, Perkins GD, Gates S, et al. Effect of intravenous beta-2 agonist treatment on clinical outcomes in acute respiratory distress syndrome (BALTI-2): a multicentre, randomised controlled trial[J]. Lancet, 2012, 379(9812): 229-235. DOI: 10.1016/S0140-6736(11)61623-1.

Popular Papers
© 2022 - 2024 Zhongnan Medical Journal Press of Zhongnan Hospital of Wuhan University|Support: Yufu Technology
About NM | Contact us